19 - 25 August 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Are we close to a cure?
Cladribine (Mavenclad) gets European licence for highly active relapsing MS
The European Commission has granted cladribine (Mavenclad) a marketing authorization for the treatment of highly active relapsing MS. This follows an earlier recommendation from the European Medicines Agency.
MS Trust link: Cladribine gets European licence